Diagnostics

Shuttle Diagnostics (a wholly-owned subsidiary of Shuttle Pharma) aims to develop pretreatment diagnostic blood tests for prostate cancer patients. The first is a PC-Rad test for predicting outcomes following radiation therapy for localized prostate cancer, while the second, PSMA-B ligand, is a theranostic molecule offering diagnosis and therapeutics for metastatic prostate cancer.

Prognostic Insights

There are currently no available tests on the market that are predictive of success for a specific treatment. Our diagnostics approach is to offer prognosis and guide treatment decisions, with the goal of providing clinicians and patients with a means of measuring the potential for success of RT for their cancer treatment.

Prevalence

The American Cancer Society estimates that 1 in 8 men will be diagnosed with prostate cancer during his lifetime. The National Cancer Institute of the National Institutes of Health (NIH) Surveillance, Epidemiology, and End Results (SEER) database estimated that approximately 268,000 men were diagnosed with prostate cancer in the U.S. in 2022 and approximately 30% of prostate cancer patients (~66,000) with localized disease received radiation therapy for cancer treatment.